LSX 2025

R&D

Bolstering CAR-T therapies by tackling CRS, with Teresa Whal...

In interview with Teresa Whalen, the CEO of CytoAgents, a clinical-stage drug development company working on a treatment for cytokine release syndrome

Digital

Agentic AI buoys all stakeholders in oncology, with Eron Kel...

At LSX 2025, Eron Kelly, CEO of Concert AI, discussed the work his Boston-based start-up is doing in oncology.

R&D

Interview at LSX 25 with Steffen Sebastian Bolz

A different approach to obesity treatment, with Steffen-Seba...

At LSX 2025, editor-in-chief Jonah Comstock connected with Dr Steffen Sebastian-Bolz, chief science officer at Aphaia Pharma.

R&D

Interview at LSX 25 with Alison Fenney feature

Why Regeneron is giving away sequencing “for free”, with Ali...

Alison Fenney, executive director of strategic partnerships and business operations at Regeneron Genetics Center, discusses free genetic sequencing.

Oncology

News and advice from an investor-CEO, with Milenko Cicmil

pharmaphorum caught up with Milenko Cicmil to talk about Tasca Therapeutics’ news at LSX: their first patient dosed for lead asset CP-383.

R&D

Six things we learned about the obesity market at LSX 2025

In LSX's Obesity Science and Innovation forum, experts gave the inside scoop on the challenges and opportunities that remain in GLP-1s.